Novel Liver Steroid Slows Brain Tumor Growth

Laboratory studies at Johns Hopkins have dramatically confirmed the power of a chemical discovered from the liver of sharks to slow the formation of new blood vessels destined to feed brain cancers as well as other tumors.

Squalamine, previously shown to have antibiotic and anti-cancer activity, inhibited the growth of brain cancers called gliomas implanted in the flanks of rats by disabling blood vessel growth, or angiogenesis, say the authors of the studies, published in the July 1 issue of the journal Cancer Research.

"Our results suggest that squalamine may be well suited for humans in the treatment of brain tumors and other diseases characterized by and dependent on new blood vessel growth," says Henry Brem, M.D., director of neurosurgical oncology at Hopkins and senior author of the study. "It dramatically slowed blood vessel formation without damaging healthy cells or embryonic development."

Named for the shark genus Squalus, squalamine was discovered in 1992 by scientists who founded Magainin Pharmaceuticals, which processes the chemical and funded the Hopkins studies. Squalamine is the first of a new class of naturally occurring molecules, aminosterols, under development for human therapies.

Squalamine is isolated from the tissues of the dog shark. It blocks or interferes with several steps in a cascade of events involved in blood vessel growth. Based on the Hopkins laboratory work, it is currently in Phase I clinical trials at the University of Texas (San Antonio) and at Georgetown Cancer Center.

In laboratory tests, squalamine proved to be as effective as the chemotherapeutic agent carmustine in slowing the growth of gliomas, the most common and deadly brain tumors, in rats. Squalamine also slowed the growth of new blood vessels caused by tumors in rabbits' eyes, slowed the growth of endothelial cells in rat brain tissue and constricted the tiny blood vessels in chick embryos. The latter ves

Contact: Karen Infeld
Johns Hopkins Medical Institutions

Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( http://www.frost.com/sublib/display-report.do?id=P86A-01-00-00-00&src=PR ), finds that ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
Cached News: